8:34AM PharmAthene: Theraclone Sciences announces initiation of Phase 2a trial of TCN-202 for the prevention of human cytomegalovirus infection (PIP) 2.10 : Theraclone Sciences announced that it has dosed the first patient in a Phase 2a clinical trial of TCN-202 for the prevention of human cytomegalovirus infection in solid organ transplant recipients. TCN-202 is a recombinant, fully human monoclonal antibody discovered using the Company's proprietary I-STAR platform. On Aug 1, 2013, Theraclone Sciences and PharmAthene announced a definitive merger agreement.
Market Data 
Markets 
AI
